Report
Our reports provide latest industry trends, forecasts, company profiles, competitive landscape, and strategic insights.
Europe Helicobacter Pylori (H. pylori) Non-invasive Testing Market Forecast to 2028 – COVID-19 Impact and Regional Analysis – by Test Type (Serology, Stool Antigen, and Urea Breath), Test Method (Laboratory Based and Point-of-Care), and End User (Hospitals, Clinics, and Diagnostic Laboratories)
- Report Code : BMIRE00027543
- Pages : 129
The helicobacter pylori (H. pylori) non-invasive testing market in Europe is expected to grow from US$ 198.40 million in 2022 to US$ 244.01 million by 2028; it is estimated to grow at a CAGR of 3.5% from 2022 to 2028.
Awareness Among Individuals Regarding Diagnosis of H. pylori Fuel Europe Helicobacter Pylori (H. pylori)
Diagnosis of H. pylori infection is performed by invasive (endoscopy and endoscopic biopsy for histopathology, culture, and rapid urease test) and non-invasive (urea breath tests, stool antigen test, and serological tests) methods. The diagnostic decisions are based on the prevalence of H. pylori infection and the number of incidences of age-related gastric cancer. For instance, non-invasive techniques are preferred mostly when the incidence of gastric cancer is low. However, endoscopy is recommended for patients who have a high probability of being diagnosed with gastric cancer, such as patients above 60 years of age or younger patients in a few European countries, or patients with a family history of gastric cancer, or countries with a high incidence of gastric cancer. Further, precise accuracy is obtained by using multiple diagnostic tests. Although these tests have high accuracy, endoscopy-based diagnostic methods are not recommended for screening purposes, mainly due to their invasiveness, high cost, and unavailability. However, in a few European countries, endoscopy is recommended for patients over the age of 45 years who have a high chance of developing gastric cancer. Thus, governments of various European countries are boosting awareness of the diagnosis of H. pylori, which is expected to fuel the market growth.
Further, in 2020, RedHill Biopharma launched a nationwide H. pylori disease state educational field led by its sales team. The launch is intended to provide greater awareness to healthcare professionals regarding the risk of H. pylori infection and the growing resistance of H. pylori to standard care of antibiotics, which leads to 25-40% failure of current therapies.
Market Overview
As per the Elsevier B.V. report, H. pylori infects ~25% of the German population and causes gastritis that becomes more complicated with peptic ulcer disease, gastric adenocarcinoma, or mucosa-associated lymphoid tissue (MALT) lymphoma annually. According to the National Institute of Health (NIH) report, H. pylori infection causes chronic inflammation that significantly increases the risk of developing duodenal and gastric ulcer disease and gastric cancer. Additionally, H. pylori infection is the strongest known risk factor for gastric cancer and is the second-leading cause of cancer-related deaths globally. As per the same report, ~15,500 people annually have gastric cancer, with a decreasing number of incidences and a 5-year survival rate of 30-35%. Moreover, Germany has no gastric cancer prevention programs, resulting in the disease being diagnosed frequently in locally advanced stages. Such aforementioned factors are responsible for the growth of the Helicobacter pylori (H. pylori) non-invasive testing market.
Europe Helicobacter Pylori (H. pylori) Non-invasive Testing Market Revenue and Forecast to 2028 (US$ Million)
Europe Helicobacter Pylori (H. pylori) Non-invasive Testing Market Segmentation
The Europe helicobacter pylori (H. pylori) non-invasive testing market is segmented on test type, test method, end user, and country.
Based on test type, the Europe Helicobacter pylori (H. pylori) non-invasive testing market is segmented into serology, stool antigen, and urea breathe. In 2022, the urea breath segment is expected to hold the largest share of the market. Based on test method, the Europe Helicobacter pylori (H. pylori) non-invasive testing market is bifurcated into laboratory based and point of care. The laboratory based segment is expected to hold a larger share of the market in 2022. Based on end user, the Europe Helicobacter pylori (H. pylori) non-invasive testing market is segmented into hospitals, clinics, and diagnostic laboratories. The diagnostic laboratories segment is expected to hold the largest share of the market in 2022. Based on country, the market is segmented into France, Germany, Italy, the UK, Spain, and the Rest of Europe. Further, Germany dominated the market in 2022. Abbott Laboratories; Bio-Rad Laboratories Inc.; CerTest Biotec; Coris BioConcept; DiaSorin S.p.A.; Meridian Bioscience Inc.; QuidelOrtho Corporation; Sekisui Diagnostics; Shenzhen Zhonghe Headway Bio-Sci & Tech Co., Ltd; and Thermo Fisher Scientific Inc. are the leading companies operating in the helicobacter pylori (H. pylori) non-invasive testing market in Europe.
TABLE OF CONTENTS
1. Introduction
1.1 Scope of the Study
1.2 The Insight Partners Research Report Guidance
1.3 Market Segmentation
1.3.1 Europe Helicobacter Pylori (H. pylori ) Non-invasive Testing Market – By Test Type
1.3.2 Europe Helicobacter Pylori (H. pylori) Non-invasive Testing Market – By Test Method
1.3.3 Europe Helicobacter Pylori (H. pylori) Non-invasive Testing Market – By End User
1.3.4 Europe Helicobacter Pylori (H. pylori ) Non-invasive Testing Market – By Country
2. Key Takeaways
3. Research Methodology
3.1 Coverage
3.2 Secondary Research
3.3 Primary Research
4. Europe Helicobacter Pylori (H. pylori ) Non-invasive Testing Market – Market Landscape
4.1 Overview
4.2 Europe PEST Analysis
4.3 Experts Opinion
5. Europe Helicobacter Pylori (H. pylori ) Non-Invasive Testing Market – Key Industry Dynamics
5.1 Key Market Drivers
5.1.1 Increasing prevalence of H. pylori bacterial infection
5.1.2 New Product Launches & FDA Approvals for Noninvasive Tests
5.1.3 Spreading Awareness Among Individuals Regarding Diagnosis of H. pylori
5.1.4 Rise in Investments by Pharmaceutical Companies
5.2 Key Market Restraints
5.2.1 Low Diagnosis Rate
5.3 Key Market Opportunities
5.3.1 Increasing Number of Conferences and Events for Research
5.3.2 Introduction of Artificial Intelligence
5.4 Future Trends
5.4.1 Increasing Use of Home-Based POC Devices
5.4.2 Diagnosis for Resistance
5.5 Impact Analysis
6. Helicobacter pylori (H. pylori ) Non-Invasive Testing Market– Europe Analysis
6.1 Europe Helicobacter pylori (H. pylori) Non-Invasive Testing Market Revenue Forecast and Analysis
7. Europe Helicobacter pylori (H. pylori ) Non-Invasive Testing Market Analysis– by Test Type
7.1 Overview
7.2 Europe Helicobacter pylori (H. pylori ) Non-invasive Testing Market, By Test Type 2022 & 2028 (%)
7.3 Serology Test
7.3.1 Overview
7.3.2 Europe Serology Test Market Revenue and Forecasts to 2028 (US$ Mn)
7.4 Stool Antigen Test
7.4.1 Overview
7.4.2 Europe Stool Antigen Test Market Revenue and Forecasts to 2028 (US$ Mn)
7.5 Urea Breath Test
7.5.1 Overview
7.5.2 Europe Urea Breath Test Market Revenue and Forecasts to 2028 (US$ Mn)
8. Europe Helicobacter pylori (H. pylori ) Non-Invasive Testing Market Analysis– by Test Method
8.1 Overview
8.2 Europe Helicobacter pylori (H. pylori) Non-invasive Testing Market, By Test Method 2022 & 2028 (%)
8.3 Laboratory Based Tests
8.3.1 Overview
8.3.2 Europe Laboratory Based Tests Market Revenue and Forecasts to 2028 (US$ Mn)
8.4 Point Of Care Tests
8.4.1 Overview
8.4.2 Europe Point of Care Tests Market Revenue and Forecasts to 2028 (US$ Mn)
9. Europe Helicobacter pylori (H. pylori ) Non-invasive Testing Market Analysis– by End User
9.1 Overview
9.2 Europe Helicobacter pylori (H. pylori ) Non-invasive Testing Market, By End User 2018 & 2028 (%)
9.3 Hospitals
9.3.1 Overview
9.3.2 Europe Hospitals Market Revenue and Forecasts to 2028 (US$ Mn)
9.4 Clinics
9.4.1 Overview
9.4.2 Europe Clinics Market Revenue and Forecasts to 2028 (US$ Mn)
9.5 Diagnostic Laboratories
9.5.1 Overview
9.5.2 Europe Diagnostic Laboratories Market Revenue and Forecasts to 2028 (US$ Mn)
10. Europe Helicobacter Pylori (H. pylori ) Non-invasive Testing Market Revenue and Forecasts to 2028 – Country Analysis
10.1 Overview
10.1.1 Europe: Helicobacter Pylori (H. pylori ) Non-invasive Testing Market, by Country, 2022 & 2028 (%)
10.1.1.1 Germany: Helicobacter Pylori (H. pylori ) Non-invasive Testing Market – Revenue and Forecast to 2028 (US$ Million)
10.1.1.1.1 Overview
10.1.1.1.2 Germany: Helicobacter Pylori (H. pylori ) Non-invasive Testing Market – Revenue and Forecast to 2028 (US$ Million)
10.1.1.1.3 Germany: Helicobacter Pylori (H. pylori ) Non-invasive Testing Market, by Test Type – Revenue and Forecast to 2028 (US$ Million)
10.1.1.1.4 Germany: Helicobacter Pylori (H. pylori ) Non-invasive Testing Market, by Test Method– Revenue and Forecast to 2028 (US$ Million)
10.1.1.1.5 Germany: Helicobacter Pylori (H. pylori ) Non-invasive Testing Market, by End User– Revenue and Forecast to 2028 (US$ Million)
10.1.1.2 France: Helicobacter Pylori (H. pylori ) Non-invasive Testing Market – Revenue and Forecast to 2028 (US$ Million)
10.1.1.2.1 Overview
10.1.1.2.2 France: Helicobacter Pylori (H. pylori ) Non-invasive Testing Market – Revenue and Forecast to 2028 (US$ Million)
10.1.1.2.3 France: Helicobacter Pylori (H. pylori ) Non-invasive Testing Market, by Test Type – Revenue and Forecast to 2028 (US$ Million)
10.1.1.2.4 France: Helicobacter Pylori (H. pylori ) Non-invasive Testing Market, by Test Method– Revenue and Forecast to 2028 (US$ Million)
10.1.1.2.5 France: Helicobacter Pylori (H. pylori ) Non-invasive Testing Market, by End User– Revenue and Forecast to 2028 (US$ Million)
10.1.1.3 UK: Helicobacter Pylori (H. pylori ) Non-invasive Testing Market – Revenue and Forecast to 2028 (US$ Million)
10.1.1.3.1 Overview
10.1.1.3.2 UK: Helicobacter Pylori (H. pylori ) Non-invasive Testing Market – Revenue and Forecast to 2028 (US$ Million)
10.1.1.3.3 UK: Helicobacter Pylori (H. pylori ) Non-invasive Testing Market, by Test Type – Revenue and Forecast to 2028 (US$ Million)
10.1.1.3.4 UK: Helicobacter Pylori (H. pylori ) Non-invasive Testing Market, by Test Method– Revenue and Forecast to 2028 (US$ Million)
10.1.1.3.5 UK: Helicobacter Pylori (H. pylori ) Non-invasive Testing Market, by End User– Revenue and Forecast to 2028 (US$ Million)
10.1.1.4 Italy: Helicobacter Pylori (H. pylori ) Non-invasive Testing Market – Revenue and Forecast to 2028 (US$ Million)
10.1.1.4.1 Overview
10.1.1.4.2 Italy: Helicobacter Pylori (H. pylori ) Non-invasive Testing Market – Revenue and Forecast to 2028 (US$ Million)
10.1.1.4.3 Italy: Helicobacter Pylori (H. pylori ) Non-invasive Testing Market, by Test Type – Revenue and Forecast to 2028 (US$ Million)
10.1.1.4.4 Italy: Helicobacter Pylori (H. pylori ) Non-invasive Testing Market, by Test Method– Revenue and Forecast to 2028 (US$ Million)
10.1.1.4.5 Italy: Helicobacter Pylori (H. pylori ) Non-invasive Testing Market, by End User– Revenue and Forecast to 2028 (US$ Million)
10.1.1.5 Spain: Helicobacter Pylori (H. pylori ) Non-invasive Testing Market – Revenue and Forecast to 2028 (US$ Million)
10.1.1.5.1 Overview
10.1.1.5.2 Spain: Helicobacter Pylori (H. pylori ) Non-invasive Testing Market – Revenue and Forecast to 2028 (US$ Million)
10.1.1.5.3 Spain: Helicobacter Pylori (H. pylori ) Non-invasive Testing Market, by Test Type – Revenue and Forecast to 2028 (US$ Million)
10.1.1.5.4 Spain: Helicobacter Pylori (H. pylori ) Non-invasive Testing Market, by Test Method– Revenue and Forecast to 2028 (US$ Million)
10.1.1.5.5 Spain: Helicobacter Pylori (H. pylori ) Non-invasive Testing Market, by End User– Revenue and Forecast to 2028 (US$ Million)
10.1.1.6 Rest of Europe: Helicobacter Pylori (H. pylori ) Non-invasive Testing Market – Revenue and Forecast to 2028 (US$ Million)
10.1.1.6.1 Overview
10.1.1.6.2 Rest of Europe: Helicobacter Pylori (H. pylori ) Non-invasive Testing Market – Revenue and Forecast to 2028 (US$ Million)
10.1.1.6.3 Rest of Europe: Helicobacter Pylori (H. pylori ) Non-invasive Testing Market, by Test Type – Revenue and Forecast to 2028 (US$ Million)
10.1.1.6.4 Rest of Europe: Helicobacter Pylori (H. pylori ) Non-invasive Testing Market, by Test Method– Revenue and Forecast to 2028 (US$ Million)
10.1.1.6.5 Rest of Europe: Helicobacter Pylori (H. pylori ) Non-invasive Testing Market, by End User– Revenue and Forecast to 2028 (US$ Million)
11. Helicobacter Pylori (H. Pylori ) Non-Invasive Testing Market–Industry Landscape
11.1 Overview
11.2 Growth Strategies in the Helicobacter Pylori (H. Pylori ) Non-Invasive Testing Market
11.3 Inorganic Growth Strategies
11.3.1 Overview
11.4 Organic Growth Strategies
11.4.1 Overview
12. Company Profile
12.1 DiaSorin S.p.A.
12.1.1 Key Facts
12.1.2 Business Description
12.1.3 Products and Services
12.1.4 Financial Overview
12.1.5 SWOT Analysis
12.1.6 Key Developments
12.2 Meridian Bioscience, Inc.
12.2.1 Key Facts
12.2.2 Business Description
12.2.3 Products and Services
12.2.4 Financial Overview
12.2.5 SWOT Analysis
12.2.6 Key Developments
12.3 QuidelOrtho Corporation
12.3.1 Key Facts
12.3.2 Business Description
12.3.3 Products and Services
12.3.4 Financial Overview
12.3.5 SWOT Analysis
12.3.6 Key Developments
12.4 Abbott Laboratories
12.4.1 Key Facts
12.4.2 Business Description
12.4.3 Products and Services
12.4.4 Financial Overview
12.4.5 SWOT Analysis
12.4.6 Key Developments
12.5 Thermo Fisher Scientific Inc.
12.5.1 Key Facts
12.5.2 Business Description
12.5.3 Products and Services
12.5.4 Financial Overview
12.5.5 SWOT Analysis
12.5.6 Key Developments
12.6 CerTest Biotec
12.6.1 Key Facts
12.6.2 Business Description
12.6.3 Products and Services
12.6.4 Financial Overview
12.6.5 SWOT Analysis
12.6.6 Key Developments
12.7 Sekisui Diagnostics
12.7.1 Key Facts
12.7.2 Business Description
12.7.3 Products and Services
12.7.4 Financial Overview
12.7.5 SWOT Analysis
12.7.6 Key Developments
12.8 Coris BioConcept
12.8.1 Key Facts
12.8.2 Business Description
12.8.3 Products and Services
12.8.4 Financial Overview
12.8.5 SWOT Analysis
12.8.6 Key Developments
12.9 Shenzhen Zhonghe Headway Bio-Sci & Tech Co., Ltd.
12.9.1 Key Facts
12.9.2 Business Description
12.9.3 Products and Services
12.9.4 Financial Overview
12.9.5 SWOT Analysis
12.9.6 Key Developments
12.10 Bio-Rad Laboratories, Inc.
12.10.1 Key Facts
12.10.2 Business Description
12.10.3 Products and Services
12.10.4 Financial Overview
12.10.5 SWOT Analysis
12.10.6 Key Developments
13. Appendix
13.1 About The Insight Partners
13.2 Glossary of Terms
LIST OF TABLES
Table 1. Germany: Helicobacter Pylori (H. pylori) Non-invasive Testing Market, by Test Type – Revenue and Forecast to 2028 (US$ Million)
Table 2. Germany: Helicobacter Pylori (H. pylori) Non-invasive Testing Market, by Test Method– Revenue and Forecast to 2028 (US$ Million)
Table 3. Germany: Helicobacter Pylori (H. pylori) Non-invasive Testing Market, by End User – Revenue and Forecast to 2028 (US$ Million)
Table 4. France: Helicobacter Pylori (H. pylori) Non-invasive Testing Market, by Test Type – Revenue and Forecast to 2028 (US$ Million)
Table 5. France: Helicobacter Pylori (H. pylori) Non-invasive Testing Market, by Test Method– Revenue and Forecast to 2028 (US$ Million)
Table 6. France: Helicobacter Pylori (H. pylori) Non-invasive Testing Market, by End User– Revenue and Forecast to 2028 (US$ Million)
Table 7. UK: Helicobacter Pylori (H. pylori) Non-invasive Testing Market, by Test Type – Revenue and Forecast to 2028 (US$ Million)
Table 8. UK: Helicobacter Pylori (H. pylori) Non-invasive Testing Market, by Test Method– Revenue and Forecast to 2028 (US$ Million)
Table 9. UK: Helicobacter Pylori (H. pylori) Non-invasive Testing Market, by End User– Revenue and Forecast to 2028 (US$ Million)
Table 10. Italy: Helicobacter Pylori (H. pylori) Non-invasive Testing Market, by Test Type – Revenue and Forecast to 2028 (US$ Million)
Table 11. Italy: Helicobacter Pylori (H. pylori) Non-invasive Testing Market, by Test Method– Revenue and Forecast to 2028 (US$ Million)
Table 12. Italy: Helicobacter Pylori (H. pylori) Non-invasive Testing Market, by End User– Revenue and Forecast to 2028 (US$ Million)
Table 13. Spain: Helicobacter Pylori (H. pylori) Non-invasive Testing Market, by Test Type – Revenue and Forecast to 2028 (US$ Million)
Table 14. Spain: Helicobacter Pylori (H. pylori) Non-invasive Testing Market, by Test Method– Revenue and Forecast to 2028 (US$ Million)
Table 15. Spain: Helicobacter Pylori (H. pylori) Non-invasive Testing Market, by End User– Revenue and Forecast to 2028 (US$ Million)
Table 16. Rest of Europe: Helicobacter Pylori (H. pylori) Non-invasive Testing Market, by Test Type – Revenue and Forecast to 2028 (US$ Million)
Table 17. Rest of Europe: Helicobacter Pylori (H. pylori) Non-invasive Testing Market, by Test Method– Revenue and Forecast to 2028 (US$ Million)
Table 18. Rest of Europe: Helicobacter Pylori (H. pylori) Non-invasive Testing Market, by End User– Revenue and Forecast to 2028 (US$ Million)
Table 19. Recent Inorganic Growth Strategies in the Helicobacter Pylori (H. Pylori) Non-Invasive Testing Market
Table 20. Recent Organic Growth Strategies in the Helicobacter Pylori (H. Pylori) Non-Invasive Testing Market
Table 21. Glossary of Terms
LIST OF FIGURES
Figure 1. Europe Helicobacter Pylori (H. pylori ) Non-invasive Testing Market Segmentation
Figure 2. Europe Helicobacter Pylori (H. pylori ) Non-invasive Testing Market, By Country
Figure 3. Europe Helicobacter Pylori (H. pylori) Non-invasive Testing Market Overview
Figure 4. Urea Breath Segment Held Largest Share of Test Type Segment in Europe Helicobacter Pylori (H. pylori) Non-invasive Testing Market
Figure 5. Italy is Expected to Show Remarkable Growth During the Forecast Period
Figure 6. Europe: PEST Analysis
Figure 7. Experts Opinion
Figure 8. Europe Helicobacter pylori Non-Invasive Testing Market Impact Analysis of Driver and Restraints
Figure 9. Europe Helicobacter pylori (H. pylori) Non-Invasive Testing Market– Revenue Forecast and Analysis – 2020 – 2028
Figure 10. Europe Helicobacter pylori (H. pylori) Noninvasive Testing Market, by Test Type 2022 & 2028 (%)
Figure 11. Europe Serology Test Market Revenue and Forecasts to 2028 (US$ Mn)
Figure 12. Europe Stool Antigen Test Market Revenue and Forecasts to 2028 (US$ Mn)
Figure 13. Europe Urea Breath Test Market Revenue and Forecasts to 2028 (US$ Mn)
Figure 14. Europe Helicobacter pylori (H. pylori) Noninvasive Testing Market, by Test Method 2022 & 2028 (%)
Figure 15. Europe Laboratory Based Tests Market Revenue and Forecasts to 2028 (US$ Mn)
Figure 16. Europe Point Of Care Tests Market Revenue and Forecasts to 2028 (US$ Mn)
Figure 17. Europe Helicobacter pylori (H. pylori) Noninvasive Testing Market, by End User 2018 & 2028 (%)
Figure 18. Europe Hospitals Market Revenue and Forecasts to 2028 (US$ Mn)
Figure 19. Europe Clinics Market Revenue and Forecasts to 2028 (US$ Mn)
Figure 20. Europe Diagnostic Laboratories Market Revenue and Forecasts to 2028 (US$ Mn)
Figure 21. Europe: Helicobacter Pylori (H. pylori) Non-invasive Testing Market, by Key Country – Revenue (2022) (US$ Million)
Figure 22. Europe: Helicobacter Pylori (H. pylori) Non-invasive Testing Market, by Country, 2022 & 2028 (%)
Figure 23. Germany: Helicobacter Pylori (H. pylori) Non-invasive Testing Market – Revenue and Forecast to 2028 (US$ Million)
Figure 24. France: Helicobacter Pylori (H. pylori) Non-invasive Testing Market – Revenue and Forecast to 2028 (US$ Million)
Figure 25. UK: Helicobacter Pylori (H. pylori) Non-invasive Testing Market – Revenue and Forecast to 2028 (US$ Million)
Figure 26. Italy: Helicobacter Pylori (H. pylori) Non-invasive Testing Market – Revenue and Forecast to 2028 (US$ Million)
Figure 27. Spain: Helicobacter Pylori (H. pylori) Non-invasive Testing Market – Revenue and Forecast to 2028 (US$ Million)
Figure 28. Rest of Europe: Helicobacter Pylori (H. pylori) Non-invasive Testing Market – Revenue and Forecast to 2028 (US$ Million)
Figure 29. Growth Strategies in the Helicobacter Pylori (H. Pylori) Non-Invasive Testing Market
● Save and reduce time carrying out entry-level research by identifying the growth, size, leading players and segments in the Europe helicobacter pylori (H. pylori) non-invasive testing market
● Highlights key business priorities in order to assist companies to realign their business strategies
● The key findings and recommendations highlight crucial progressive industry trends in the Europe helicobacter pylori (H. pylori) non-invasive testing market, thereby allowing players across the value chain to develop effective long-term strategies
● Develop/modify business expansion plans by using substantial growth offering developed and emerging markets
● Scrutinize in-depth Europe market trends and outlook coupled with the factors driving the helicobacter pylori (H. pylori) non-invasive testing market, as well as those hindering it
● Enhance the decision-making process by understanding the strategies that underpin commercial interest with respect to client products, segmentation, pricing and distribution
The List of Companies – Europe Helicobacter Pylori (H. pylori) Non-invasive Testing Market
● Abbott Laboratories
● Bio-Rad Laboratories Inc.
● CerTest Biotec; Coris BioConcept
● Coris BioConcept
● DiaSorin S.p.A.
● Meridian Bioscience Inc.
● QuidelOrtho Corporation
● Sekisui Diagnostics
● Shenzhen Zhonghe Headway Bio-Sci & Tech Co., Ltd
● Thermo Fisher Scientific Inc.
At 3.5% CAGR, the Europe Helicobacter Pylori (H. pylori) Non-invasive Testing Market is speculated to be worth US$ 244.01 Million by 2028, says The Insight Partners
According to The Insight Partners’ research, the Europe helicobacter pylori (H. pylori) non-invasive testing market was valued at US$ 198.40 million in 2022 and is expected to reach US$ 244.01 million by 2028, registering an annual growth rate of 3.5% from 2022 to 2028. Increasing prevalence of H. pylori bacterial infection and new product launches & FDA approvals for noninvasive tests are the critical factors attributed to the market expansion.
About 50% of the population is infected by H. pylori infection. The infection is usually developed during infant but remains asymptomatic, with long-standing clinical symptoms including gastritis, peptic ulcer disease, and stomach cancer.
Also, according to World Health Organization (WHO), developing countries have about 90% high prevalence rate in developing countries, whereas, in developed countries, the prevalence rate is low, i.e., 50%. The H. pylori infection rate in females was found to be 42.7% as compared to 46.3% in males. Moreover, it was significantly higher in adults than in children, 48.6% and 32.6%, respectively.
Further, the prevalence of the gastric disease is significantly higher in the geriatric population as aging increases the risk of H. pylori infection. Increased age leads to thinning of the stomach lining, thus allowing the bacteria to pass through the protective lining that contributes to the growing prevalence of infection among older people. With the subsequent increase in geriatric population, the demand for primary care services, including screening, assessment, and management of clinical and functional comorbidities, is increasing. These statistics determine an increase in the need for diagnostics in various regions across the region. Hence, boosting the growth of the Helicobacter pylori noninvasive testing market during the forecast period.
On the contrary, very low diagnosis rate hurdles the growth of Europe helicobacter pylori (H. pylori) non-invasive testing market.
Based on test type, the Europe Helicobacter pylori (H. pylori) non-invasive testing market is segmented into serology, stool antigen, and urea breathe. In 2022, the urea breath segment is expected to hold the largest share of the market in 2022 with a share of 45.2%, amassing US$ 9 89.76 million. It is projected to garner US$ 113.31 million by 2028 to expand at 4.0% CAGR during 2022–2028. Based on test method, the Europe Helicobacter pylori (H. pylori) non-invasive testing market is bifurcated into laboratory based and point of care. The laboratory based segment is expected to hold a larger share of the market in 2022 with a share of 75.2%, amassing US$ 149.27 million. It is projected to garner US$ 185.99 million by 2028 to expand at 3.7% CAGR during 2022–2028. Based on end user, the Europe Helicobacter pylori (H. pylori) non-invasive testing market is segmented into hospitals, clinics, and diagnostic laboratories. The diagnostic laboratories segment is expected to hold the largest share of the market in 2022 with a share of 58.9%, amassing US$ 116.78 million. It is projected to garner US$ 145.48 million by 2028 to expand at 3.7% CAGR during 2022–2028. Our regional analysis states that Germany captured 21.4% market share in 2022. It was assessed at US$ 42.38 million in 2022 and is likely to hit US$ 49.66 million by 2028, exhibiting a CAGR of 2.7% during the forecast period.
Key players dominating the Europe helicobacter pylori (H. pylori) non-invasive testing market are Abbott Laboratories; Bio-Rad Laboratories Inc.; CerTest Biotec; Coris BioConcept; DiaSorin S.p.A.; Meridian Bioscience Inc.; QuidelOrtho Corporation; Sekisui Diagnostics; Shenzhen Zhonghe Headway Bio-Sci & Tech Co., Ltd; and Thermo Fisher Scientific Inc.
Below are mentioned a few key market developments by major players:
In Dec 2021, Thermo Fisher Scientific Inc. announced that it has completed its acquisition of PPD, Inc. (Nasdaq: PPD), a leading global provider of clinical research services to the biopharma and biotech industry, for $17.4 billion. In April 2020, Meridian Bioscience, Inc. has completed the acquisition of Exalenz Bioscience Ltd., the Modiin, Israel-based provider of the BreathID Breath Test Systems, a urea breath test platform for the detection of Helicobacter pylori.
Related Reports
- $3,000.00 – $5,000.00
